

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on Jan. 31, 2001.

*Eny L. Cleland*  
Attorney for Applicant(s)

*Jan. 31, 2001*  
Date of Signature

127E NE  
RECEIVED  
2/7/01

FEB 07 2001

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Jeffrey L. Cleland, Amy Lim, and Michael Frank Powell

Assignee: Genentech, Inc.

Title: COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES

Serial No.: 08/846,933 Filing Date: April 30, 1997

Examiner: Hines, J. Art Unit: 1645

Docket No.: M-9169-3C US

COMMISSIONER FOR PATENTS  
Washington, D. C. 20231

**AMENDMENT**

Dear Sir:

In response to the Final Office Action dated October 19, 2000, Applicants respectfully requests reconsideration of the above-identified application in view of the following amendments and remarks. This Amendment is accompanied by a Petition for Withdrawal of Finality of Office Action and a Request for Extension of Time (one month).

**In the Claims:**

*AMEND*

Please delete Claims 1, 4, 6, 7, and 23-27, and substitute therefore the following revised versions of these claims.

1. (Five Times Amended) A composition comprising a homogeneous population of polylactide or poly (lactide-co-glycolide) (PLGA) polymer microspheres encapsulating an antigen, wherein said homogeneous population is produced from an emulsion comprising aqueous antigen and a polylactide or PLGA polymer, and
  - (a) the polymer has a ratio of lactide to glycolide of about 100:0 to 50:50 weight percent;
  - (b) the polymer has an inherent viscosity of about 0.1 to 1.2 dL/g;